Prostatic Acid Phosphatase
EmergingPAP is a historical prostate cancer marker now most significant as the target antigen for sipuleucel-T, the first FDA-approved cancer vaccine.
PAP was the original prostate cancer blood test before PSA took over. Its modern significance comes from being the specific target of the first-ever FDA-approved cancer vaccine, which trains the immune system to attack cells carrying this protein — a nice full-circle connection to the PSA story.
Prostatic acid phosphatase (PAP) is an enzyme produced by prostate tissue, historically the primary prostate cancer marker before PSA (discussed much earlier) became standard practice.
PAP has been largely replaced by PSA for routine prostate cancer monitoring due to PSA's superior sensitivity, but PAP has a genuinely notable second act as a specific tumor antigen target for cancer immunotherapy.
PAP is not routinely measured as a diagnostic blood test in current prostate cancer management; its modern relevance is primarily as the target antigen exploited by a specific approved immunotherapy.
PAP is the target antigen for sipuleucel-T (Provenge), the first FDA-approved therapeutic cancer vaccine (2010), which trains a patient's own immune cells (antigen-presenting cells exposed to a PAP-GM-CSF fusion protein) to attack PAP-expressing prostate cancer cells, demonstrating a survival benefit in metastatic castration-resistant prostate cancer.
Demonstrated a survival benefit in metastatic castration-resistant prostate cancer as the basis of an approved immunotherapy.
- PMC. (2021). Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T.
- PMC. (2011). PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine.